A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice | Zendy

Mingfan Geng | Zendy; Yuxin Li | Zendy; Fangyuan Gao | Zendy; Le Sun | Zendy; Xue Yang | Zendy; Rui Wang | Zendy; Jialiang Chen | Zendy; Qun Zhang | Zendy; Gang Wan | Zendy; Xianbo Wang | Zendy

Open Access

A scoring model predicts hepatitis B e antigen seroconversion in chronic hepatitis B patients treated with nucleos(t)ide analogs: real-world clinical practice

Author(s) -

Mingfan Geng,

Yuxin Li,

Fangyuan Gao,

Le Sun,

Xue Yang,

Rui Wang,

Jialiang Chen,

Qun Zhang,

Gang Wan,

Xianbo Wang

Publication year - 2017

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2017.06.016

Subject(s) - medicine , confidence interval , hbeag , odds ratio , seroconversion , hepatitis b , hazard ratio , cohort , concordance , proportional hazards model , gastroenterology , immunology , hepatitis b virus , hbsag , antibody , virus

This study developed and validated a non-invasive scoring model to predict 1-year hepatitis B e antigen (HBeAg) seroconversion in response to nucleos(t)ide analog (NA) treatment in NA-naïve patients with HBeAg-positive chronic hepatitis B (CHB).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research